February 21, 2013

PET tracer predicts resistance to hormone therapy for breast cancer

Evan Godt writes in the February 20, 2013 Molecular Imaging 18F-labeled fluoromisonidazole (18F-FMISO) PET/CT can be used during breast cancer treatment planning to predict primary endocrine resistance in estrogen receptor (ER)-positive cancers, according to a study published Feb. 11 in the Journal of Nuclear Medicine .